[Clinical study on a new cephalosporin: CGP 9000 (cefroxadine)].
CGP 9000 (cefroxadine), a new cephalosporine derived from N-acyl-3-alkoxy-7-amino-3-cefem-4-carboxylic acid for exclusively oral use, has been experimented on 67 patients, 41 adults and 20 children. CGP 9000 appeared to possess good therapeutic activity, even in low doses: its rapid absorption and moderate sero-protein bond are a guarantee of an immediate and almost total bioavailability.
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D001682:Biological Availability; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use*; D002515:Cephradine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003556:Cystitis / Q000188:drug therapy; D004341:Drug Evaluation; D004886:Erysipelas / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy; D010309:Parotitis / Q000188:drug therapy; D012541:Scarlet Fever / Q000188:drug therapy
D002511:Cephalosporins; C012671:cefroxadine; D002515:Cephradine
Ricerca clinica su una nuova cefalosporina: CGP 9000 (cefroxadina).